Modelling overdispersion and Markovian features in count data
暂无分享,去创建一个
Mats O. Karlsson | Raymond Miller | Elodie L. Plan | Iñaki F. Trocóniz | Raymond Miller | M. Karlsson | I. Trocóniz | E. Plan
[1] David C. Heilbron,et al. Zero-Altered and other Regression Models for Count Data with Added Zeros , 1994 .
[2] Meindert Danhof,et al. Pharmacodynamic Analysis of the Anticonvulsant Effects of Tiagabine and Lamotrigine in Combination in the Rat , 2004, Epilepsia.
[3] Meindert Danhof,et al. A pharmacodynamic Markov mixed‐effect model for the effect of temazepam on sleep , 2000, Clinical pharmacology and therapeutics.
[4] Carl W David,et al. Stirling's Approximation , 2007 .
[5] Pravin K. Trivedi,et al. Regression Analysis of Count Data , 1998 .
[6] R. Miller,et al. Exposure‐response Analysis for Spontaneously Reported Dizziness in Pregabalin‐treated Patient With Generalized Anxiety Disorder , 2008, Clinical pharmacology and therapeutics.
[7] Eva M Shipp,et al. Web-based data collection: detailed methods of a questionnaire and data gathering tool , 2006, Epidemiologic perspectives & innovations : EP+I.
[8] Lewis B. Sheiner,et al. A Population Pharmacokinetic–Pharmacodynamic Analysis of Repeated Measures Time-to-Event Pharmacodynamic Responses: The Antiemetic Effect of Ondansetron , 1999, Journal of Pharmacokinetics and Biopharmaceutics.
[9] Christopher J. Godfrey,et al. Mixed Effects Modeling Analysis of Count Data , 2006 .
[10] Matts Kågedal,et al. Modelling a Spontaneously Reported Side Effect by Use of a Markov Mixed-Effects Model , 2005, Journal of Pharmacokinetics and Pharmacodynamics.
[11] David R. Cox,et al. Some remarks on overdispersion , 1983 .
[12] Pravin K. Trivedi,et al. Regression Analysis of Count Data: Preface , 1998 .
[13] Brian Corrigan,et al. Exposure‐response analysis of pregabalin add‐on treatment of patients with refractory partial seizures , 2003, Clinical pharmacology and therapeutics.
[14] L B Sheiner,et al. Quantitative characterization of therapeutic index: Application of mixed‐effects modeling to evaluate oxybutynin dose–efficacy and dose–side effect relationships , 1999, Clinical pharmacology and therapeutics.
[15] John P Elder,et al. Epidemiologic Perspectives & Innovations Open Access a Demonstration of Modeling Count Data with an Application to Physical Activity , 2022 .
[16] C. J. Adkins. An introduction to thermal physics , 1987 .
[17] Marta Pérez-Casany,et al. Overdispersed and underdispersed Poisson generalizations , 2005 .